Tracy A Marko1, Brandon J Diessner2, Logan G Spector3. 1. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 2. School of Public Health, University of Minnesota, Minneapolis, Minnesota. 3. Department of Pediatric Epidemiology, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: Osteosarcoma (OS) is the most common primary malignant bone tumor in many countries, with metastatic disease responsible for most patient deaths. This study compares the prevalence of metastatic OS at diagnosis across countries to inform the critical question of whether diagnostic delay or tumor biology drives metastases development prior to diagnosis. PROCEDURE: A literature search of the PubMed database was conducted to compare the prevalence of metastatic disease at the time of OS diagnosis between countries. A pooled prevalence with 95% confidence intervals was calculated for each study meeting inclusion criteria. Studies were grouped for analysis based on human development index (HDI) scores. RESULTS: Our analysis found an 18% (95% confidence interval [CI]: 15%, 20%) average global pooled proportion of metastasis at OS diagnosis. The average prevalence of metastasis at diagnosis increased as HDI groupings decreased, with very high HDI, high HDI, and medium/low HDI groups found to be 15% (95% CI: 13%, 17%), 20% (95% CI: 14%, 28%), and 31% (95% CI: 15%, 52%), respectively. CONCLUSIONS: Our evidence suggests there is a biological baseline for metastatic OS at diagnosis, which is observed in countries with very high HDI. In countries with medium/low HDI, where there are more barriers to accessing healthcare, the higher prevalence of metastasis may result from treatment delay or an artificial prevalence inflation due to patients with less severe symptoms not presenting to clinic. Additional research in countries with medium/low HDI may reveal that earlier detection and treatment could improve patient outcomes in those countries.
BACKGROUND:Osteosarcoma (OS) is the most common primary malignant bone tumor in many countries, with metastatic disease responsible for most patient deaths. This study compares the prevalence of metastatic OS at diagnosis across countries to inform the critical question of whether diagnostic delay or tumor biology drives metastases development prior to diagnosis. PROCEDURE: A literature search of the PubMed database was conducted to compare the prevalence of metastatic disease at the time of OS diagnosis between countries. A pooled prevalence with 95% confidence intervals was calculated for each study meeting inclusion criteria. Studies were grouped for analysis based on human development index (HDI) scores. RESULTS: Our analysis found an 18% (95% confidence interval [CI]: 15%, 20%) average global pooled proportion of metastasis at OS diagnosis. The average prevalence of metastasis at diagnosis increased as HDI groupings decreased, with very high HDI, high HDI, and medium/low HDI groups found to be 15% (95% CI: 13%, 17%), 20% (95% CI: 14%, 28%), and 31% (95% CI: 15%, 52%), respectively. CONCLUSIONS: Our evidence suggests there is a biological baseline for metastatic OS at diagnosis, which is observed in countries with very high HDI. In countries with medium/low HDI, where there are more barriers to accessing healthcare, the higher prevalence of metastasis may result from treatment delay or an artificial prevalence inflation due to patients with less severe symptoms not presenting to clinic. Additional research in countries with medium/low HDI may reveal that earlier detection and treatment could improve patient outcomes in those countries.
Authors: Janet Y K Yang; Frankie W T Cheng; K C Wong; Vincent Lee; W K Leung; Matthew M K Shing; Shekhar M Kumta; C K Li Journal: Hong Kong Med J Date: 2009-12 Impact factor: 2.227
Authors: D Adamkova Krakorova; K Vesely; I Zambo; S Tucek; J Tomasek; A Jureckova; P Janicek; J Cerny; L Pazourek; S Ondrusek; I Selingerova Journal: Klin Onkol Date: 2012
Authors: Daniel C Allison; Scott C Carney; Elke R Ahlmann; Andrew Hendifar; Sant Chawla; Alex Fedenko; Constance Angeles; Lawrence R Menendez Journal: Sarcoma Date: 2012-03-18
Authors: Chenan Zhang; Helen M Hansen; Eleanor C Semmes; Julio Gonzalez-Maya; Libby Morimoto; Qingyi Wei; William C Eward; Suzanne B DeWitt; Jillian H Hurst; Catherine Metayer; Adam J de Smith; Joseph L Wiemels; Kyle M Walsh Journal: Bone Date: 2019-09-13 Impact factor: 4.398
Authors: Megan M Cleary; Narendra Bharathy; Jinu Abraham; Jin-Ah Kim; Erin R Rudzinski; Joel E Michalek; Charles Keller Journal: Mol Cancer Ther Date: 2021-04-14 Impact factor: 6.261